SecBot SecBot
8-K ·Filed Sep 4, 2026

PDSB

PDS Biotechnology Corp
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001140361-26-035809
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The amendment signals acute liquidity pressure and gives the note holder near-total control over future equity capital. Monitor for potential Nasdaq delisting (cure period extension suggests non-compliance) and any restructuring or reverse split. The company's ability to raise non-dilutive capital is now effectively eliminated.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$0.3000
T+0 close · Sep 4, 2026 · via day close
Latest settled
+248.33%
T+20 · $1.05 · next T+60 in 15d
Vs SPY
+246.62%
α at T+20
Latest observation
+279.03%
T+22 · FF3 residual α
  1. T+0 · Sep 8 $0.3000entry
  2. T+1 · 2mo ago −2.33%α −1.87% · $0.2930
  3. T+5 · 2mo ago +95.10%α +96.22% · $0.5853
  4. T+20 · 6w ago +248.33%α +246.62% · $1.05
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology amended its $6M promissory note with YA II PN, Ltd., tightening repayment terms: 100% of net proceeds from any non-ATM equity financing must be paid to the holder within 5 business days, and ATM proceeds are largely swept weekly. The Nasdaq listing deficiency cure period was extended from 75 to 180 days, signaling ongoing compliance risk. The amendment reflects severe liquidity constraints and limits the company's ability to retain capital from future equity raises.

Key Facts

  • Original promissory note principal: $6,000,000, issued June 15, 2026.
  • Amendment requires 100% of net cash proceeds from any non-ATM equity or equity-linked financing to be paid to the holder within 5 business days.
  • ATM net proceeds must be remitted weekly; excess over next installment is split 60% to holder / 40% retained by company.
  • Nasdaq listing deficiency cure period extended from 75 to 180 days.
  • Amendment effective upon payment of the September 14, 2026 installment amount in full.

Financial Impact

$6M promissory note represents ~50% of $12M market cap; cash flow sweep provisions severely restrict the company's ability to fund operations from equity raises.

cash_flowliquiditydebt

Risk Factors

  • Nasdaq delisting risk (cure period extension indicates ongoing deficiency)
  • Liquidity crisis, equity raise proceeds cannot be retained for operations
  • Potential default or forced restructuring if installment payments are missed
  • Further dilution if the company attempts any equity-linked financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-035809
Document: ef20081442_8k.htm0001140361-26-035809
Document: 0001140361-26-035809-index-headers.html0001140361-26-035809
Document: 0001140361-26-035809-index.html0001140361-26-035809
Document: 0001140361-26-035809.txt0001140361-26-035809

Track record

28 reports on PDSB

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 10 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026